Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ISB 2001
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Ichnos Glenmark Innovation
Deal Size : Undisclosed
Deal Type : Collaboration
Certara and Ichnos Glenmark Collaborate On Cancer Drug Dosing Optimization
Details : ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
September 18, 2024
Lead Product(s) : ISB 2001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Ichnos Glenmark Innovation
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Arvinas
Deal Size : Undisclosed
Deal Type : Partnership
Arvinas picks Certara for Its Targeted Protein Degradation Research
Details : Certara’s D360 platform enables Arvinas to accelerate lead identification and optimization processes for oncology, neurodegenerative diseases, and therapies for “undruggable” targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Arvinas
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Trifarotene
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Galderma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Certara's Simcyp population-based Simulator was used to support Galderma’s successful U.S. FDA new drug application for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.
Product Name : Aklief
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : Trifarotene
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Galderma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : Defence Materials Technology Centre
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 05, 2020
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : Defence Materials Technology Centre
Deal Size : Undisclosed
Deal Type : Collaboration